Search
Now showing items 291-300 of 591
Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds.
(ELSEVIER, 2021-03-29)
The use of intracellular antibodies as templates to derive surrogate compounds is an important objective because intracellular antibodies can be employed initially for target validation in pre-clinical assays and subsequently ...
The Development of Therapeutic Radiographers in Imaging and Adaptive Radiotherapy Through Clinical Trial Quality Assurance.
(ELSEVIER SCIENCE LONDON, 2021-03-22)
AIMS: Adaptive radiotherapy (ART) is an emerging advanced treatment option for bladder cancer patients. Therapeutic radiographers (RTTs) are central to the successful delivery of this treatment. The purpose of this work ...
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology.
(ELSEVIER, 2021-02-06)
The field of immuno-oncology has expanded rapidly over the past decade, but key questions remain. How does tumour-immune interaction regulate disease progression? How can we prospectively identify patients who will benefit ...
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
(ELSEVIER SCI LTD, 2021-02-10)
BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing ...
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
(AMER ASSOC CANCER RESEARCH, 2021-01-01)
Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia ...
APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable.
(AMER ASSOC CANCER RESEARCH, 2021-06-15)
The apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) family protects against infection by degrading incoming viral genomes through cytosine deamination. Here, we review how the potential to unleash these ...
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.
(MDPI, 2021-01-19)
Prostate cancer is one of the most frequent cancers in men and is a common cause of cancer-related death. Despite significant progress in the diagnosis and treatment of this tumor, patients who relapse after radical ...
Lights and Shadows in Immuno-Oncology Drug Development.
(MDPI, 2021-02-09)
The rapidly evolving landscape of immuno-oncology (IO) is redefining the treatment of a number of cancer types. IO treatments are becoming increasingly complex, with different types of drugs emerging beyond checkpoint ...
A simple digital image analysis system for automated Ki67 assessment in primary breast cancer.
(WILEY, 2021-08-01)
AIMS: Ki67 is a well-established immunohistochemical marker associated with cell proliferation that has prognostic and predictive value in breast cancer. Quantitative evaluation of Ki67 is traditionally performed by assessing ...
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.
(Elsevier BV, 2021-01-11)
Early-phase cancer clinical trials are becoming increasingly accessible for patients with advanced cancer who have exhausted standard treatment options and later phase trial options. Many of these trials mandate research ...